MAPT and Alzheimer disease: The recent advances in blood-based biomarkers of pathological changes in AD, such as plasma beta-amyloid (Aβ) and phosphorylated tau (p-tau), have made these biomarkers more accessible and their evaluation more prevalent [7, 8].